MRC1 and central nervous system cancer: Of these latter, only one had MSI, suggesting that mechanisms different from defective MMR system may lead to a hypermutational status in gliomas and that the recent proposal to use MMR immunohistochemistry to identify hypermutated cases for immunotherapy should be considered with caution [43].